Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pigmentation Disorder Clear all
Completed Phase 2 Interventional

Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo

NCT00134368
View directory record Official record
Conditions
Vitiligo
Interventions
Etanercept
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Sep 3, 2026, 8:55 PM EDT
Completed No phase listed Observational

Mast Cell Connect: A Registry for Patients With Mastocytosis

NCT02620254
View directory record Official record
Conditions
Mastocytosis
Interventions
Not listed
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
Not listed
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser

NCT02427724
View directory record Official record
Conditions
Lentigo
Interventions
lidocaine 2.5%/prilocaine 2.5% topical anesthetic, lidocaine 7%/tetracaine 7% topical anesthetic, placebo vehicle, Q-switched 532nm Laser
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 3, 2026, 8:55 PM EDT
Completed No phase listed Observational

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

NCT00040222
View directory record Official record
Conditions
Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 3, 2026, 8:55 PM EDT
Completed No phase listed Observational

Molecular Epidemiology of Cutaneous Malignant Melanoma

NCT00341991
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
15,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Phase 2 Interventional

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

NCT00239135
View directory record Official record
Conditions
Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 3, 2026, 8:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cause of Pigment Dispersion Syndrome

NCT00005919
View directory record Official record
Conditions
Glaucoma, Healthy, Pigment Dispersion Syndrome
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Efficacy of Bakuchiol in Treating PIH

NCT06833996
View directory record Official record
Conditions
Post Inflammatory Hyperpigmentation
Interventions
Bakuchiol, Vehicle
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Cutaneous Effects of Deep Ultraviolet A +/- High-Energy Visible Blue Light Exposure

NCT06654102
View directory record Official record
Conditions
Skin Pigmentation, Photobiology
Interventions
Deep UVA Irradiation, Deep UVA+HEV Blue Light Irradiation
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Union City, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 3, 2026, 8:55 PM EDT
Completed No phase listed Observational

Molecular Mechanisms and Diagnosis of Mastocytosis

NCT00336076
View directory record Official record
Conditions
Mastocytosis
Interventions
Collection of blood and bone marrow
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots

NCT01149876
View directory record Official record
Conditions
Hyperpigmentation
Interventions
Nu Skin Product, Cosmetic instrument, Tretinoin cream 0.05, CeraVe moisturizer
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Polypodium Leucotomos for Melasma

NCT01162850
View directory record Official record
Conditions
Melasma
Interventions
Polypodium Leucotomos, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Sep 3, 2026, 8:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Questionnaire and Laboratory Data on Vitiligo Vulgaris

NCT01206374
View directory record Official record
Conditions
Vitiligo Vulgaris
Interventions
Not listed
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

NCT04103060
View directory record Official record
Conditions
Vitiligo
Interventions
Cerdulatinib 0.37% gel, Vehicle gel
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Irvine, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Single-Center Open-Label Study of 1064 nm for Nonablative Skin Rejuvenation

NCT03421691
View directory record Official record
Conditions
Skin Pigment, Photoaging
Interventions
excel V Laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
35 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

NCT02272998
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
ponatinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 3, 2026, 8:55 PM EDT
Active, not recruiting Phase 2 Interventional

Daily Topical Rapamycin for Vitiligo

NCT05342519
View directory record Official record
Conditions
Vitiligo
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Not applicable Interventional

A Novel Regimen for Treatment and Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color

NCT06938815
View directory record Official record
Conditions
Post Inflammatory Hyperpigmentation
Interventions
Pigment Balancing Peel, Discoloration Defense Serum, LHA Cleansing Gel, Hydrating B5 Gel, Daily Brightening Sunscreen
Other
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

NCT02772276
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart, MB-102-- two doses of 130 mg 24 hours apart, Iohexol, QuantumLeap, Radiance, Brilliance (1 or 2 sensors), Brilliance (2-part sensor)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Edgewater, Florida • Orlando, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stress Response Pathways in Vitiligo

NCT02797574
View directory record Official record
Conditions
Vitiligo
Interventions
Punch Biopsy at a Lesional Site, Punch Biopsy at a Non- Lesional site
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

NCT03468855
View directory record Official record
Conditions
Vitiligo
Interventions
ATI-50002 topical solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Encinitas, California • Los Angeles, California • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A 4-week Study Investigating Two Targeted Brightening Serum (A and B) Versus 4% Hydroquinone in Women With Mild to Severe Full-face Hyperpigmentation

NCT07644871
View directory record Official record
Conditions
Hyperpigmentation, Melasma, Dark Spots
Interventions
Facial Cleanser, Facial Moisturizer, Sunscreen SPF 55
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
20 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 3, 2026, 8:55 PM EDT
Recruiting No phase listed Observational

PRecision Integrated Saturation Monitor

NCT07686341
View directory record Official record
Conditions
CHD - Congenital Heart Disease, Single Ventricle Heart Disease
Interventions
vital sign monitoring
Device
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
0 Months to 12 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 3, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome

NCT00001596
View directory record Official record
Conditions
Albinism, Inborn Errors of Metabolism, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Pulmonary Fibrosis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
William Gahl, M.D.
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 3, 2026, 8:55 PM EDT